Our studies with both 153Sm and 223Ra show that, compared to radiotherapy with beta-emitters, radiotherapy with alpha-emitters safely delivers much higher energy to tumor tissue in a more localized manner, providing a rationale for investigating the combination of 223Ra and PSA-TRICOM for the treatment of mCRPC. Here, KLK3 is linked to neoplasm.